open access

Vol 72, No 4 (2021)
Clinical vignette
Submitted: 2021-04-02
Accepted: 2021-05-08
Early publication date: 2021-05-31
Get Citation

Pembrolizumab-induced diabetes

Rumaisa Banatwalla1, Omar Zuhair Kirresh2, Fahad Wali Ahmed2
DOI: 10.5603/EP.a2021.0053
·
Pubmed: 34057191
·
Endokrynol Pol 2021;72(4):414-415.
Affiliations
  1. Specialist Registrar in Endocrinology and Diabetes, King’s College Hospital NHS Foundation Trust, London, United Kingdom
  2. Consultant in Diabetes and Endocrinology, Royal Sussex County Hospital, University Hospitals Sussex NHS Foundation Trust, Brighton, United Kingdom

open access

Vol 72, No 4 (2021)
Clinical Vignette
Submitted: 2021-04-02
Accepted: 2021-05-08
Early publication date: 2021-05-31

Abstract

Not required for Clinical Vignette.

Abstract

Not required for Clinical Vignette.

Get Citation

Keywords

pembrolizumab; diabetes; diabetic ketoacidosis; malignant melanoma; check-point inhibitors

About this article
Title

Pembrolizumab-induced diabetes

Journal

Endokrynologia Polska

Issue

Vol 72, No 4 (2021)

Article type

Clinical vignette

Pages

414-415

Early publication date

2021-05-31

Page views

640

Article views/downloads

267

DOI

10.5603/EP.a2021.0053

Pubmed

34057191

Bibliographic record

Endokrynol Pol 2021;72(4):414-415.

Keywords

pembrolizumab
diabetes
diabetic ketoacidosis
malignant melanoma
check-point inhibitors

Authors

Rumaisa Banatwalla
Omar Zuhair Kirresh
Fahad Wali Ahmed

References (6)
  1. Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports. PLoS One. 2016; 11(7): e0160221.
  2. Ishida M, Iwai Y, Tanaka Y, et al. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol Lett. 2002; 84(1): 57–62.
  3. Colli ML, Hill JLE, Marroquí L, et al. PDL1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons-α and-γ via IRF1 induction. EBioMedicine. 2018; 36: 367–375.
  4. Clotman K, Janssens K, Specenier P, et al. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus. J Clin Endocrinol Metab. 2018; 103(9): 3144–3154.
  5. Stamatouli AM, Quandt Z, Perdigoto AL, et al. Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes. 2018; 67(8): 1471–1480.
  6. Eshet Y, Baruch EN, Shapira-Frommer R, et al. Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case-Control Study. Cancer Immunol Res. 2018; 6(12): 1453–1458.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl